Investigating methotrexate dosing and side effects for Burkitt lymphoma in Malawi
Official title: Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
Funded at Univ of North Carolina Chapel Hill · NIH-10650283 · Data updated 2026-11-12
This study is looking to make treatments better for kids and young adults with Burkitt lymphoma in Sub-Saharan Africa by testing the safest dose of a chemotherapy drug called methotrexate and finding out how it works in the body, while also listening to patients about any side effects they experience.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | June 1, 2019 |
| Project end | April 30, 2026 |
| Funding year | 2023 |
| Award (this year) | $142,831 |
| NIH project number | 5K01TW011191-05 |
| Project ID | NIH-10650283 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children and young adults diagnosed with Burkitt lymphoma in Sub-Saharan Africa.
✕Less likely to help
Patients with other types of cancers or those outside the age range of 0-21 years may not benefit from this research.
What this research studies
This research focuses on improving treatment for Burkitt lymphoma, a common cancer in children and young adults in Sub-Saharan Africa. The project will involve a pilot clinical trial to find the highest safe dose of methotrexate, a key chemotherapy drug. Additionally, researchers will develop a model to understand how the drug behaves in the body and create a tool to assess side effects from the patient's perspective. This comprehensive approach aims to enhance treatment protocols and ultimately improve survival rates.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with Burkitt lymphoma.
How similar studies have gone: Previous research has shown promising results in optimizing cancer treatments in resource-limited settings, indicating potential success for this approach.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Westmoreland, Katherine Douglas — Univ of North Carolina Chapel Hill
- Study coordinator: Westmoreland, Katherine Douglas
Related research
Other NIH-funded projects on the same topics.
-
Investigating methotrexate dosing and effects for Burkitt lymphoma in Malawi
This study is looking to make treatments better for kids and young adults with Burkitt lymphoma by testing the safest dose of a chemotherapy drug called methotrexate and finding out how it works in the body, all while keeping an eye on how patients feel during treatment.
-
Organoid model to study how malaria and EBV drive Burkitt lymphoma in children
A study uses human tonsillar organoids to understand how malaria parasite infection and EBV together may cause a type of lymphoma in children from sub-Saharan Africa.
-
Enriching tumor-derived EBV DNA to build a diagnostic test for endemic Burkitt lymphoma (eBL)
A study to develop a blood-based test that specifically detects tumor-derived EBV DNA to improve early diagnosis of endemic Burkitt lymphoma in children.
-
Improving diagnosis of Burkitt lymphoma in children using blood tests.
This study is looking at a new way to help doctors quickly and accurately diagnose endemic Burkitt lymphoma in children by checking for a specific virus in their blood, which could lead to faster treatment and better outcomes.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.